One of the most concerning aspects of genetic testing company 23andMe filing for Chapter 11 bankruptcy, Professor Sara Gerke writes in a new article published in BMJ, is the range of information the company holds. Along with her co-authors, Gerke explores the issues presented by the genetic information, such as from saliva samples, self-reported health and personal information, biometric information, and other basic information controlled by 23andMe. They argue customers made a deal to share information, at some privacy risk, in exchange for potential ancestry and health-related insights, but that does not absolve the company from protecting privacy in bankruptcy.
